Stem Cell Market To Grow At A CAGR Of 7.9% | Growing Demand For Regenerative Medicine Increases Market Growth: Growth Plus Reports
NEW YORK, October 27, 2021 / PRNewswire / –
The Global Stem Cell Market is expected to reach approximately US $ 24.4 billion by 2031 due to the increasing number of clinical trials of stem cells for the treatment of several chronic diseases and technological advancements in stem cell therapy.
Request a sample report of this report: https://growthplusreports.com/product/stem-cells-market/
Growing influx of stem cell research funding from different organizations is driving the growth of the stem cell market. For example, in February 2021, Notch Therapeutics announced the closing of US $ 85 million Series A funding. With their assistance, Notch will continue to develop iPSC-derived T cell therapy product candidates and clinical readiness for the company’s proprietary Engineered Thymic Niche (ETN) platform. . Likewise, in june 2020, Sana Biotechnology Inc., a spin-off company of Harvard Medical School (a cell therapy start-up) received US $ 700 million of funds. The company is dedicated to the development of regenerative medicine therapies using stem cells.
The global stem cell market has been analyzed from four angles: cell source, type, application, and region.
Extracts from “By cell source segmentation”
On the basis of cell source, the stem cells market has been segmented into human embryonic stem cells, adult stem cells, induced pluripotent stem cells, and other types of stem cells. Adult stem cells held the largest share of the stem cell market in 2020. Major factors driving the growth of this segment include low chance of rejection by the body and high success rate.
Extracts from “Segmentation by region”
Regionally, the global stem cell market has been segmented into North America, Europe, Asia Pacific, and the rest of the world (RoW). North America held the largest share of the global stem cell market in 2020. The major factors attributable to the growth of the stem cell market in this region include the availability of greater funding for stem cell research, the increasing prevalence of chronic diseases and relatively more drug adoption.
Access the full report on: Stem Cells Market by Cell Source (Human Embryonic Stem Cells, Adult Stem Cells, and Induced Pluripotent Stem Cells), Type (Allogeneic Stem Cell Therapy & Autologous Stem Cell Therapy), Application (Regenerative Medicine & Drug Discovery & Development) – Global Outlook and Forecast 2021-2031
Extracts from “Competitive Landscape”
- Pfizer Inc.
- Osiris Therapeutics, Inc. (Smith & Neveu)
- ReNeuron plc Group
- GlaxoSmithKline plc
- Holostem Therapy Avanzate Srl
- Astellas Pharma inc
- Therapeutics Pluristem Inc
- Regen BioPharma
VALUE PROPOSALS RELATED TO THE REPORT:
- Powered with free analyst hours and expert interviews with every report
- Comprehensive quantitative and qualitative information at segment and sub-segment level
- Trends and outlook for the impact of Covid 19
- Granular information at global / regional / country level
- In-depth information on market dynamics (drivers, constraints, opportunities) and the business environment
- Global coverage of the competitive landscape
- Winning imperatives
- Exhaustive coverage of “strategic developments” recorded by the main market players
- Distributor landscape assessment
- Price information
- Customer rating
- Analysis of investments and initiatives
- “Company profile” of key players
- Talk to industry experts
Healthcare Market Trend Reports:
Sports medicine market– Advances in 3D printed implants and high incidence of sports-related injuries are likely to drive the growth of sports drugs market.
Cancer Diagnostics Market– Growing awareness of early detection of cancer associated with increasing number of cancer diagnostic centers which are expected to drive the growth of cancer diagnostics market
Breast Imaging Market– Awareness of early diagnosis of breast cancer likely to boost the growth of the breast imaging market
About Us: Growth + Reports is part of GRG Health, a global health knowledge services company. We are proud to be members of EPhMRA (European Pharmaceutical Marketing Research Association).
The Growth + service portfolio leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create solutions scalable and revolutionary that prepare them for future growth and success.
We have been recognized by the prestigious CEO Magazine as âthe most innovative healthcare market research company in 2020.
SOURCE GRG Health